AEON BIOPHARMA
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is dedicated to developing novel and proprietary treatment paradigms in order to improve patient outcomes and drive increased value for patients, physicians, and payers.
AEON BIOPHARMA
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.aeonbiopharma.com
Total Employee:
1+
Status:
Active
Contact:
+1-949-298-2211
Email Addresses:
[email protected]
Total Funding:
45 M USD
Technology used in webpage:
Domain Not Resolving Euro Google Tag Manager Google Analytics Global Site Tag HSTS ReCAPTCHA Cloudflare Hosting Google Universal Analytics ReCAPTCHA V2
Similar Organizations
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Hansa Biopharma
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company that leverages its unique enzyme technology.
Osteal Therapeutics
Osteal Therapeutics is a clinical stage specialty pharmaceutical company developing novel treatments for orthopedic infections.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Investors List
Daewoong Pharmaceutical
Daewoong Pharmaceutical investment in Post-IPO Debt - AEON Biopharma
Official Site Inspections
http://www.aeonbiopharma.com Semrush global rank: 5.27 M Semrush visits lastest month: 1.46 K
- Host name: 104.21.6.61
- IP address: 104.21.6.61
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AEON Biopharma"
Breaking new ground with therapeutic botulinum toxin - AEON …
Our team is on a mission to realize the untapped possibilities of therapeutic neurotoxins with our proprietary botulinum toxin complex. Our deep expertise in commercial neurotoxins guides us …See details»
AEON Biopharma - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1-949-298-2211 AEON Biopharma is a biopharmaceutical company focused on the …See details»
AEON Biopharma - Investor Relations
Aug 19, 2024 AEON Biopharma is the only company dedicated exclusively to the use of botulinum toxins for therapeutic-only indications. With ABP-450 (prabotulinumtoxinA), we are …See details»
AEON Biopharma, Inc. | LinkedIn
AEON Biopharma, Inc. | 827 followers on LinkedIn. Breaking New Ground | AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment ...See details»
AEON Biopharma - AEON Biopharma Reports Fourth Quarter and …
Mar 29, 2024 The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To …See details»
AEON Biopharma, Inc. (AEON) Company Profile & Overview
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical …See details»
Investors - AEON Biopharma
REQUEST A MEETING WITH MANAGEMENT > follow us on linkedin; CompanySee details»
AEON Biopharma to Become Publicly Listed via Merger with
Dec 13, 2022 [email protected]. Investor Contact: Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected]. Priveterra Contacts: …See details»
AEON Biopharma Announces Closing of Business Combination …
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline …See details»
Marc Forth - AEON Biopharma
Marc Forth has served as our Chief Executive Officer since May 2019. Prior to AEON Biopharma, Mr. Forth was the Senior Vice President of Allergan PLC and Division Head for the U.S. Neurosciences, Urology and Medical Dermatology …See details»
Pipeline, clinical trials, and partnerships | AEON Biopharma
Cervical dystonia is a chronic condition that impacts roughly 50,000 Americans and causes painful and debilitating twisting movements of the neck and shoulders. 3 There is currently no cure for …See details»
AEON Biopharma Announces Strategic Reprioritization to Pursue a ...
Jul 9, 2024 – Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled …See details»
AEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History
Find the latest AEON Biopharma, Inc. (AEON) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
AEON Biopharma, Inc. (AEON) Stock Price, Quote & News - Stock …
2 days ago About AEON. AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection …See details»
AEON Biopharma Announces Preliminary Top-Line Results from …
May 3, 2024 The primary endpoint of mean reduction in monthly migraine days (MMD) over the period 13-24 weeks in a total of 325 analyzed patients randomized across three arms showed …See details»
Shawn Park - AEON Biopharma
Park has been a director at Daewoong since March 2023 and was a director at Daewoong Co., Ltd., an affiliate of Daewoong, from March 2021 to March 2023. In addition, Mr. Park is …See details»
AEON Biopharma, Inc. (AEON) Stock Price, News, Quote & History
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical …See details»
AEON Biopharma Reports Positive Topline Results from Phase
Sep 23, 2022 [email protected]. Investor Contact: Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected]. Photos accompanying this …See details»
Chad Oh, MD - AEON Biopharma
Chad Oh, MD, our Chief Medical Officer, has more than 30 years of therapeutic clinical development experience in both industry and academia with a focus on CNS, infectious, …See details»